The Chemours Company reported full-year 2025 net sales of $5.8 billion, flat versus 2024, and a net loss attributable to Chemours of $386 million ($2.57 per diluted share), compared with net income of $69 million ($0.46 per diluted share) in 2024. Adjusted EBITDA for 2025 was $742 million versus $768 million a year earlier. Chemours said the 2025 net loss was primarily driven by litigation-related charges inclusive of the announced settlement with the State of New Jersey.
In Thermal & Specialized Solutions (TSS), Chemours reported record full-year 2025 net sales of $2.1 billion, up 13% from 2024, reflecting sustained Opteon refrigerants adoption. Opteon refrigerants sales rose 56% year over year to $1,264 million, which the company associated with the U.S. AIM Act stationary AC transition. Over the same period, Freon refrigerants sales declined 30% to $428 million, and Foam, Propellants & Other (FP&O) decreased 8% to $374 million. TSS full-year adjusted EBITDA increased 18% to $670 million; Chemours said higher input costs related to R32 partially offset the benefit of higher Opteon volumes and higher prices across the portfolio.
Chemours’ full-year 2026 outlook calls for consolidated net sales growth of 3% to 5% and adjusted EBITDA of $800 million to $900 million, with free cash flow conversion above 25%. Capital expenditures are expected to be $275 million to $325 million. For the first quarter of 2026, Chemours expects consolidated net sales to increase 3% to 5% sequentially and consolidated adjusted EBITDA of $120 million to $150 million, with capital expenditures around $50 million and free cash flow reflecting a use of cash not to exceed $100 million.
For TSS specifically, Chemours projects first-quarter 2026 net sales will rise sequentially in the mid-twenty to thirty percentage range, mainly due to seasonal refrigerant demand and an expected 30% to 40% increase in Opteon refrigerants sales from ongoing adoption in North America’s stationary market. TSS adjusted EBITDA is expected to be $170 million to $185 million in the first quarter.
“Our consolidated fourth quarter results delivered robust cash flow and achieved revenue performance that met our expectations, highlighted by the continued transition to Opteon refrigerants – concluding a record setting year for TSS,” said Denise Dignam, Chemours President and CEO.
